UPMC Enterprises
Corporate venture capital
UncertainLast verified 7 Nov 2026
Corporate venture capital and commercialization arm of UPMC investing across early- to growth-stage in healthcare diagnostics, therapeutics, and digital health solutions.
1 deal in the last 24 months, latest 31 Jul 2025. From its website and its deals in the news.
Key facts
- Stages
- Pre-seed, Seed, Series A, Series B, Series C+
- Sectors
- Healthtech, Biotech & pharma, Medtech
- Eligible countries
- Not stated
- Provider based in
- United States
- Timing
- Rolling applications
- Focus
- cutting-edge diagnostics and therapeutics; digital solutions in healthcare
- How to apply
- Apply route unknown
Recent deals
| Company | Round | Sectors | Amount | Role | Announced |
|---|---|---|---|---|---|
| Ultromics | Series C+ | AI & machine learning, Healthtech, Medtech | €49.3M | participant | 31 Jul 2025 |
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
As the innovation, commercialization, and venture capital arm of UPMC, a $28 billion health care provider and insurer, we maintain a flexible investment model.
https://enterprises.upmc.com/ - Sectors
Translational Sciences Investing in and supporting the development and commercialization of cutting-edge diagnostics and therapeutics. Digital Solutions
https://enterprises.upmc.com/ - Stages
The support of the UPMC system allows us to invest in companies from early- to growth-stage
https://enterprises.upmc.com/
Status history
- 7 Nov 2026: Rolling → Uncertain (freshness: investor activity)
- 6 Nov 2026: Rolling (first extraction)
Something wrong or out of date? Report an error.
Work at UPMC Enterprises? Claim this profile to confirm what you invest in.